GlassScriptPhysician profile
Zita B Yorro
NPI 1477566701
$5,762.95
in general payments reported to CMS, 2019-2025
17 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $211 · 2021: $246 · 2022: $3,070 · 2023: $585 · 2024: $752 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,472.01 | 2022-2023 | Ubrelvy |
| Novo Nordisk INC | $634.49 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.26 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $337.81 | 2022-2025 | Farxiga, Breztri |
| Amgen INC. | $262.90 | 2019-2024 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $256.46 | 2019-2022 | |
| Boston Scientific Corporation | $241.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $197.96 | 2022-2025 | |
| Lilly USA, LLC | $163.43 | 2022-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $158.91 | 2020-2025 | Nexletol |
| Horizon Therapeutics Plc | $110.53 | 2019 | |
| Merck Sharp & Dohme LLC | $106.91 | 2022-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $59.19 | 2019-2025 | Uptravi |
| Sanofi Pasteur INC. | $52.35 | 2025 | |
| Abbott Laboratories | $41.23 | 2024-2025 | Freestyle Libre 3 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.75 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $17.73 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zita Yorro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.